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A commentary on
Methamphetamine mediates immune dysregulation in a murine model of chronic viral
infection
by Sriram, U., Haldar, B., Cenna, J. M., Gofman, L., and Potula, R. (2015). Front. Microbiol. 6:793.
doi: 10.3389/fmicb.2015.00793
The recent article by Sriram et al. (2015) is one of the first studies to evaluate the effects of
methamphetamine on peripheral T cell responses, in the context of a chronic viral infection. Using
lymphocytic choriomeningitis virus (LCMV) clone 13 as a model of chronic viral infection in
mice, investigators found that exposure to methamphetamine significantly alters the expression
of peripheral T cell factors putatively involved in infection control. In particular, the expression of
programmed cell death protein-1 (PD-1), type 3 inflammatory CXC chemokine receptor (CXCR3),
and epidermal growth factor receptor (EGFR) was increased on T cell subsets from LCMV-infected
mice exposed to methamphetamine. Collectively, these immune cell changes have the potential to
adversely impact key anti-viral immune functions, such as T cell recruitment, cytokine production,
and exhaustion.
Given the high prevalence of chronic viral infections [e.g., human immunodeficiency virus
(HIV) and hepatitis C virus (HCV)] associated with methamphetamine and other substance
use disorders, including alcohol (Martínez-Raga et al., 2001), it is important to determine how
substances of abuse effect T cell responses involved in the etiology and progression of chronic
viral infection. Co-morbid substance use disorders and HIV and/or HCV infections are also often
associated with impairments in central nervous system (CNS) function (Carey et al., 2006; Loftis
et al., 2006; Butt et al., 2007; Fuller et al., 2009), which can hinder successful treatment outcomes
(Fals-Stewart, 1993; Aharonovich et al., 2003). Similarly, infectious symptoms (e.g., fatigue, pain,
and depression), potentially caused by substance abuse-related peripheral immunosuppression,
could lead to further likelihood of relapse or increased substance use. Indeed, the tendency of
adults with substance use disorders to self-medicate with alcohol and other drugs of abuse (Bolton
et al., 2009; Crum et al., 2013) could be recognized as a possible complication of untreated or
uncontrolled viral infection symptoms. These and other findings highlight the converging effects
of substances of abuse on immune function—effects that contribute to the addiction and increase
susceptibility for the progression of chronic viral infections. Despite changes in peripheral T cell
markers associated with viral clearance, Sriram et al. (2015) reported that methamphetamine
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exposure did not significantly alter viral loads in plasma or
tissues (i.e., spleen, lungs) from mice with LCMV clone 13
infection. However, it would be of interest to investigate
whether or not methamphetamine exposure contributed to
the invasion of virus into the brain, as LCMV (although
considered to be peripherally restricted) can infect the brain
and cause CNS impairments, including learning deficits
(Brot et al., 1997).
Methamphetamine and other substances of abuse alter blood
brain barrier (BBB) function (Haorah et al., 2008; Kousik et al.,
2012; Northrop and Yamamoto, 2012) and potentially increase
the invasion of peripheral viruses, such as HIV and HCV, into
the brain (e.g., Gavrilin et al., 2002; Bokemeyer et al., 2011). In
a previous study using a murine model of HIV-1 encephalitis,
Potula et al. (2006) innovatively demonstrated the presence of
CD8+ T cell infiltration in brain areas with HIV-1 monocyte-
derived macrophage infection and importantly, the impairing
effects of alcohol on viral clearance. Emerging evidence suggests
that T cells may play a critical role in these processes and in
the development of CNS damage resulting from viral infection
and co-morbid substance abuse (Gaskill et al., 2013; Coley
et al., 2015). It is noteworthy that Sriram et al. (2015) observed
increased expression of T cell markers, which among other
immune functions, play a role in the transmigration of T cells into
the CNS. For example, studies show a role for CXCR3 in CD8+ T
cell trafficking in the brain following intracranial LCMV infection
in mice (e.g., Christensen et al., 2006), and CXCR3 has been
proposed to serve as a surfacemarker for cells that have the ability
to cross the BBB (Callahan et al., 2004). Similarly, in addition
to regulating the sensitivity to alcohol (Corl et al., 2009), EGFR
activation contributes to the integrity of tight junctions between
brain endothelial cells (Chen et al., 2011), and tight junctions are
one of the most important structural elements of the BBB. Thus,
substance use disorders may exacerbate the increased trafficking
of peripheral monocytes to CNS, and in combination with
compromised BBB function, may have significant consequences
for individuals with co-morbid viral infection(s) (e.g., HCV
and/or HIV).
As an initial step to identify mechanisms by which chronic
viral infection and alcohol (ethanol; EtOH) induce abnormalities
in T cell function, potentially facilitate neuroinvasion of LCMV,
and contribute to CNS impairments, we exposed BALB/c mice
to EtOH and water (or water only) using a two-bottle choice
paradigm, followed one week later by infection with either LCMV
clone 13, LCMV Armstrong (causes acute infection), or vehicle.
Mice were monitored for 60 days post-infection and continued
to receive 24-h access to EtOH and water. Consumption of
EtOH was associated with alterations in virus-specific CD8+ T
cell expression and delayed viral clearance in mice with LCMV
clone 13 infection (Loftis et al., 2015). Research to determine the
effects of LCMV and alcohol exposure on CNS viral invasion and
behavioral outcomes is in progress. Sriram et al. (2015) aptly note
that; “LCMV has proven to be a great model to study chronic
infections in mice as they induce a robust T cell response” (p. 8).
Given that persistent CNS infection can lead to the generation
of autoimmune responses and that the presence of viral proteins
in the CNS can increase sensitivity to and susceptibility for
substance abuse (Vigorito et al., 2015), more research is needed
to provide a better understanding for the molecular basis of the
neurotoxic combination of substance abuse and chronic viral
infections, such as HCV and HIV. These investigative efforts
will be instrumental in translating basic science and preclinical
findings into clinical practice. For example, development of a
database of infectious complications associated with substance
use disorders could be established. Through the use of such a
database (e.g., listing co-morbid HCV infection and opioid use
disorder complicated by acute bacterial endocarditis, Wakeman
et al., 2014), we may be better able to correlate key clinical
observations with research findings, leading to more targeted
(and potentially more aggressive) infection treatment strategies
for patients with co-morbid substance use disorders.
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